Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Benzoate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Amarex Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2017
Lead Product(s) : Sodium Benzoate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Amarex Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Benzoate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
Details : Undisclosed
Product Name : NaBen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2014
Lead Product(s) : Sodium Benzoate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Benzoate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
Details : Undisclosed
Product Name : NaBen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2013
Lead Product(s) : Sodium Benzoate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable